UPDATE ON COVID-19 MONOCLONAL ANTIBODY TREATMENT RECOMMENDATIONS

This announcement is to make you aware of an update on COVID-19 monoclonal antibody (mAb) treatment recommendations. According to the most recent CDC projections, Omicron is estimated to account for 99.8% of new COVID-19 cases in HHS Region 2 (which includes New York, New Jersey, Puerto Rico, and US Virgin Islands). Studies have demonstrated that the monoclonal antibodies produced by Lilly (bamlanivimab plus etesevimab) and Regeneron (casirivimab plus imdevimab, REGEN-COV) are unlikely to be active against the Omicron variant. Sotrovimab appears to retain activity against the Omicron variant but is currently in limited supply.

Due to the high proportion of Omicron cases present in New York State, starting January 18, 2022 the New York State Department of Health will no longer be fulfilling provider requests for bamlanivimab with etesevimab (BAM/ETE), etesevimab by itself to pair with bamlanivimab on hand, or REGEN-COV.

We are asking providers that have BAM/ETE and REGEN-COV on-hand to pause use and maintain remaining supplies of these mAbs under proper storage conditions so that they may be used if the situation changes. If a provider can utilize testing to distinguish between variants (i.e., infections caused by Omicron vs. Delta) and can subsequently treat those individuals within the appropriate treatment window, they may continue to use product on-hand. If a provider, based on their clinical judgement and availability of product, chooses to prescribe REGEN-COV or BAM/ETE without being able to identify the variant type, they should clearly communicate the risks and benefits to the patient and communicate that the therapy may not be effective.

Providers are encouraged to review the updated Food and Drug Administration (FDA) Health Care Provider Fact Sheets for BAM/ETE and REGEN-COV for specific information regarding expected activity against the Omicron variant.

For information on monoclonal antibodies please refer to NYSDOH’s COVID-19 Monoclonal Antibody (mAb) Therapeutics Information for Providers.